A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

a study on Amyotropic Lateral Sclerosis (ALS)

Summary

Eligibility
for people ages 18-100 (full criteria)
Location
at La Jolla, California and other locations
Dates
study started
study ends around
Principal Investigator
by John Ravits
Headshot of John Ravits
John Ravits

Description

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).

Official Title

A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS)

Details

The main questions this trial aims to answer in comparing VHB937 to placebo are:

  • How long will participants live without needing permanent help from a machine to breathe after starting the trial treatment?
  • What is the change in the participant's ability to perform daily activities? This will be measured using a questionnaire called the amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R).
  • What adverse events are reported during this trial? An adverse event is any sign or symptom that participants have during a trial. Adverse events may or may not be caused by treatments in the trial. The trial doctors will check participants' ALS and general health throughout the trial.

Keywords

Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, ALS, monoclonal antibody, motor neuron disease, MND, Sclerosis, VHB937

Eligibility

You can join if…

Open to people ages 18-100

  • are 18 years of age or older
  • male or female, if of childbearing potential, strict contraception required
  • have ALS confirmed by the trial doctors using different tests.
  • have mild symptoms of ALS as measured by the ALSFRS-R questionnaire (total score >=30).
  • have had symptoms of ALS (weakness) within 24 months of taking part in this trial.
  • have not received treatment for ALS or are currently on a stable dose of an approved treatment for ALS.
  • have the ability to slowly exhale a volume of air at least 60% of what is expected for the participant's sex, height and age.

You CAN'T join if...

  • Use of other investigational drugs within 5 half-lives of screening, or within 30 days (e.g., small molecules) / or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations.
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 24 weeks after stopping study medication.
  • History or current diagnosis of cardiac conditions or ECG abnormalities indicating significant risk of safety for participants in the study.
  • Clinical evidence of liver or renal disease/injury.
  • Laboratory evidence of hematological abnormalities
  • Presence of unstable psychiatric disease, cognitive impairment, neurological disease other than ALS, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the investigator's opinion.
  • Participants that reported 'yes' on any suicidal ideation section except for the "Non-Suicidal Self-Injurious Behavior" in the past 2 years as per C-SSRS.
  • Presence of cancer, HIV, Hep B, Hep C, tuberculosis, uncontrolled diabetes
  • History of active severe respiratory disease, including Chronic Obstructive Pulmonary Disease, interstitial lung disease or pulmonary fibrosis.
  • Taking any prohibited medications

Locations

  • University of California San Diego accepting new patients
    La Jolla California 92037 United States
  • Keck Medical Center USC accepting new patients
    Los Angeles California 90033 United States

Lead Scientist at UCSD

  • John Ravits
    Professor Of Clinical, Neurosciences, Vc-health Sciences-schools. Authored (or co-authored) 120 research publications. Research interests: ALS neuroanatomic propagation · ALS molecular neuropathology · ALS genomics and transcriptome · C9orf72 ALS · Antisense oligonucleotide therapies · ALS clinical trials

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Novartis Pharmaceuticals
ID
NCT06643481
Phase
Phase 2 Amyotropic Lateral Sclerosis (ALS) Research Study
Study Type
Interventional
Participants
Expecting 225 study participants
Last Updated
Contact us about this trial